the evaluation of effectiveness of oral silymarin on memory status of patients with dementia
Phase 2
- Conditions
- Condition 1: Dementia in Alzheimer disease. Condition 2: Vascular dementia. Condition 3: Dementia in other diseases classified elsewhere.Alzheimer disease is a primary degenerative cerebral disease of unknown etiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and develops slowly but steadily over a period of several years.Vascular dementia is the result of infarction of the brain due to vascular disease, including hypertensive cerebrovascular disease. The infarcts are usually small but cumulative in their effect. Onset is usually in later life.Cases of dementia due, or presumed to be due, to causes other than Alzheimer disease or cerebrovascular disease. Onset may be at any time in life, though rarely in old age.
- Registration Number
- IRCT201505091856N5
- Lead Sponsor
- Vice-chancellor for research, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
inclusion criteria:
1. definite diagnosis of dementia by an experienced neurologist
2. at least one year has past form the time of the diagnosis
exclusion criteria:
1. illiterate persons
2. having epilepsy, cardiovascular diseases, metabolic diseases, respiratory diseases, orthopedic problems and renal failure with serum cratinin level more than 2
3. history of previous stroke
4. acute and severe state of any disease including stroke, pulmonary infection, renal disease, metabolic disturbance or trauma leading to hospitalization during the study
5. using other self care programs that are effective on memory state of patents at the same time of study intervention
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Memory status of patients. Timepoint: before and 12 weeks after intervention. Method of measurement: mini mental state examination scale.
- Secondary Outcome Measures
Name Time Method Drug side effects. Timepoint: 12 weeks after intervention. Method of measurement: history and physical examination.